Gapping up
In reaction to strong earnings/guidance: N/A.
M&A news: MEG +21.9% (Nexstar (NXST) hostile bid for Media General (MEG) complicates MEG-MDP merger), ATML +6.6% (Cypress Semi (CY) is considering offer to acquire ATML, according to Reuters), AA +4.3% (to separate into two independent, publicly-traded companies), SLH +1.3% (IHS (IHS) to make offer to acquire SLH, according to Reuters)
Other news: OGXI +17.3% (presents additional Phase 3 SYNERGY data), BLDP +16.2% (secures $17 mln contract to deploy ~300 fuel cell buses in China), GALE +6.1% (presents data from the GALE-301 Phase 2a portion of the Phase 1/2a clinical trial), RDY +5.4% (launches esomeprazole magnesium delayed-release capsules), NVO +3.7% (FDA approved the new drug application for Tresiba), HRTX +1.2% (announces oral presentation of data from completed Phase 3 MAGIC Study for SUSTOL), GLPG +0.9% (seeing modest rebound following Friday's declines)
Analyst comments: NTRA +2.2% (upgraded to Outperf at Wedbush), BSX +1% (upgraded to Buy at Needham), VRTX +1% (upgraded to Buy at Argus
)
In reaction to strong earnings/guidance: N/A.
M&A news: MEG +21.9% (Nexstar (NXST) hostile bid for Media General (MEG) complicates MEG-MDP merger), ATML +6.6% (Cypress Semi (CY) is considering offer to acquire ATML, according to Reuters), AA +4.3% (to separate into two independent, publicly-traded companies), SLH +1.3% (IHS (IHS) to make offer to acquire SLH, according to Reuters)
Other news: OGXI +17.3% (presents additional Phase 3 SYNERGY data), BLDP +16.2% (secures $17 mln contract to deploy ~300 fuel cell buses in China), GALE +6.1% (presents data from the GALE-301 Phase 2a portion of the Phase 1/2a clinical trial), RDY +5.4% (launches esomeprazole magnesium delayed-release capsules), NVO +3.7% (FDA approved the new drug application for Tresiba), HRTX +1.2% (announces oral presentation of data from completed Phase 3 MAGIC Study for SUSTOL), GLPG +0.9% (seeing modest rebound following Friday's declines)
Analyst comments: NTRA +2.2% (upgraded to Outperf at Wedbush), BSX +1% (upgraded to Buy at Needham), VRTX +1% (upgraded to Buy at Argus
)